Chemotherapy News and Research

Latest Chemotherapy News and Research

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

Researchers find healthy dose of exercise good for lymphoma patients receiving chemotherapy

A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found.

28 Oct 2009

Oncolytics Biotech receives its 33rd U.S. Patent

Oncolytics Biotech Inc. today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

27 Oct 2009

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Building on the strengths of two institutions separated by nearly 9,000 miles over two continents - both renowned in their work in the fight against cancer - the United States Agency for International Development has awarded a $500,000 grant to Fred Hutchinson Cancer Research Center to aid in the construction of the first American cancer clinic and medical-training facility in Africa.

27 Oct 2009

First child with a surgically implanted artificial humerus doing well after a year

When little Mark Blinder was diagnosed with a rare bone cancer, doctors at Lucile Packard Children's Hospital gave his parents three agonizing options: amputate the affected arm at the shoulder, irradiate the tumor and risk a second malignancy, or try a limb-preserving surgery that had never been attempted in a toddler.

27 Oct 2009

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company’s TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

27 Oct 2009

BH3 profiling can help in determining cancer's chemosensitivity

Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al. The study will be published online October 26, 2009 and in the November 2, 2009 print issue of the Journal of Cell Biology (JCB).

27 Oct 2009

Fred Hutchinson Cancer Research Center receives a $500,000 grant to construct cancer clinic in Africa

27 Oct 2009

Princeton University scientists and researchers team up to explore cancer evolution

Princeton University physical scientists will partner with researchers at four other institutions to explore the driving forces behind the evolution of cancer under a five-year, $15.2 million award from the National Cancer Institute.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer

In a review article published this month in The Oncologist, UNC's Dr. Richard M. Goldberg and a team of colleagues catalogue how the data collected in a single large comparative clinical trial testing combination chemotherapy for metastatic colorectal cancer has been used not only to benefit the patients that enrolled but also patients who subsequently developed the disease.

27 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

NCI grant to conduct innovative cancer research

Researchers find healthy dose of exercise good for lymphoma patients receiving chemotherapy

Oncolytics Biotech receives its 33rd U.S. Patent

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

Astellas enters into agreement with Medivation to develop MDV3100

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

First child with a surgically implanted artificial humerus doing well after a year

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

BH3 profiling can help in determining cancer's chemosensitivity

Fred Hutchinson Cancer Research Center receives a $500,000 grant to construct cancer clinic in Africa

Princeton University scientists and researchers team up to explore cancer evolution

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer

New significant tool to improve the quality of care for patients with brain tumors released

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

Results from Phase I dose-escalation study of AT-101 announced

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in